Tafasitamab Plus Lenalidomide Prolongs OS in Relapsed/Refractory DLBCL: RE-MIND2

Tafasitamab, a CD19-directed cytolytic antibody, combined with lenalidomide demonstrated prolonged overall survival (OS) compared to bendamustine plus rituximab or rituximab plus gemcitabine and oxaliplatin for patients with relapsed/refractory diffuse large b-cell lymphoma (DLBCL), according to findings from the RE-MIND2 study.

“In RE-MIND2, patient-level outcomes from the L-MIND study of tafasitamab plus lenalidomide were retrospectively compared with patient-level matched observational cohorts treated with National Cancer Care Network (NCCN)/European Society for Medical Oncology (ESMO)-listed systemic therapies for relapsed/refractory [DLBCL], explained Grzegorz Nowakowski, MD, Mayo Clinic, Rochester, MN, and colleagues.

Using health records, researchers collected data from eligible patients with DLBCL who received ≥2 systemic therapies, including ≥1 anti-CD20 therapy. Propensity score matching matched patients from the L-MIND study to patients in the RE-MIND2 observational cohort.

The primary analysis included 3454 patients and compared tafasitamab plus lenalidomide among patients who received any systemic therapy (n = 76 pairs), bendamustine plus rituximab (n = 75 pairs), or rituximab plus gemcitabine and oxaliplatin (n = 74 pairs). The primary end point was OS.

Study findings showed tafasitamab plus lenalidomide significantly prolonged OS vs pooled systemic therapies (hazard ratio (HR): 0.55; P = .0068), bendamustine plus rituximab (HR, 0.42; P <.0001), and rituximab plus gemcitabine and oxaliplatin (HR: 0.47; P = .0003).

In the pooled systemic therapies cohort, the median OS with tafasitamab plus lenalidomide was 34.1 months vs 11.6 months with systemic therapies. In the bendamustine plus rituximab cohort, the median OS with tafasitamab plus lenalidomide was 31.6 months vs 9.9 months with bendamustine plus rituximab. In the rituximab plus gemcitabine and oxaliplatin cohort, the median OS with tafasitamab plus lenalidomide was 31.6 months vs 11 months with rituximab plus gemcitabine and oxaliplatin.

“In conclusion, a significant clinical advantage in OS was observed in the cohort treated with tafasitamab plus lenalidomide in a clinical trial versus matched observational cohorts treated with pooled systemic therapies, [bendamustine plus rituximab], and [rituximab plus gemcitabine and oxaliplatin],” wrote Dr Nowakowski and colleagues.

“In the context of current treatments, these data further highlight the clinical value of the tafasitamab plus lenalidomide combination in patients with [relapsed/refractory] DLBCL,” they concluded.

Source:

Nowakowski GS, Yoon DH, Peters A, et al. Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. Clin Cancer Res. Published online June 8, 2022. doi:10.1158/1078-0432.CCR-21-3648.